EGFR and cancer: This observation aligns with emerging evidence that some resistant cancers can activate alternative pathways or utilize bypass signaling mechanisms to maintain proliferation despite EGFR inhibition (Chong and Janne, 2013; Sever and Brugge, 2015; Rotow and Bivona, 2017; Leonetti et al., 2019; Passaro et al., 2021; Cooper et al., 2022; Tomuleasa et al., 2024).